Quick Takeaways: Why It Matters? Presenting full SLAB trial data for GF‑1004 (a SIRT6‑based gene therapy) positions Genflow to seek an animal‑health licensing or co‑development deal in a fast‑growing pet longevity/sarcopenia niche. If the results show meaningful improvements in...
Quick Takeaways: Why It Matters? Genflow’s early canine SIRT6 data are strong enough that big animal‑health players now want a closer look, but not yet strong enough for anyone to sign a deal. The expanded web of NDAs suggests real strategic interest ...
